• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, November 18, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Five-Day Malaria Regimen Requires Targeted Evaluation Across African Programs

by
November 18, 2026
in Health
Reading Time: 2 mins read
0
Five-Day Malaria Regimen Requires Targeted Evaluation Across African Programs

Five-Day Malaria Regimen Requires Targeted Evaluation Across African Programs

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Recent guidance from the United States Centers for Disease Control and Prevention that extended artemether–lumefantrine treatment for uncomplicated malaria from three days to five days does not justify changing national guidelines across African malaria programs, according to a perspective published in Discover Public Health. Authors Faith Adedayo Adejumo and Ayomide Raphael Ijabadeniyi explain that the updated regimen was developed specifically for clinical practice within the United States. Consequently, the authors emphasize that guidance tailored to American healthcare settings cannot independently determine therapeutic protocols across diverse African national contexts.

The perspective addresses rising concerns surrounding emerging resistance and reports of declining artemether–lumefantrine efficacy. Although artemisinin partial resistance and reduced treatment efficacy have been documented at selected African study sites, the authors clarify that these localized findings do not establish that the standard three-day regimen is ineffective across the entire continent. Because evidence of reduced efficacy remains confined to specific locations, broad generalizations regarding continental treatment failure remain unsupported by the available surveillance data.

Clinical trials conducted in Africa comparing three-day and five-day artemether–lumefantrine courses have confirmed that extended regimens achieve greater overall lumefantrine exposure in patients. However, Adejumo and Ijabadeniyi highlight that increased drug exposure alone fails to demonstrate superior clinical cure rates, reduced malaria recrudescence, or practical feasibility within routine healthcare delivery. Without direct evidence showing clear therapeutic improvements or programmatic viability, pharmacological exposure metrics cannot validate adopting longer treatment courses in public health programs.

Instead of blanket adoption across African countries, the authors advocate for geographically targeted evaluations of extended artemether–lumefantrine regimens to inform evidence-based policy decisions. They stress that future research must systematically integrate therapeutic efficacy outcomes with molecular resistance surveillance, detailed pharmacokinetic data, medicine-quality verification, and thorough assessments of patient adherence and real-world implementation. Ultimately, rigorous comparative studies must establish whether extended regimens provide meaningful clinical advantages over standard artemether–lumefantrine or alternative artemisinin-based combination therapies before national treatment policies are modified.

Subject of Research: Evaluation of extended artemether–lumefantrine regimens in African malaria programs

Article Title: Responding to declining artemether lumefantrine efficacy in African malaria programs

Article References: Adejumo, F. A., & Ijabadeniyi, A. R. (2026). Responding to declining artemether lumefantrine efficacy in African malaria programs. Discover Public Health, 23(1), Article 1818. https://doi.org/10.1186/s12982-026-03259-1

Image Credits: AI Generated

DOI: 10.1186/s12982-026-03259-1

Keywords: artemether-lumefantrine, malaria treatment, antimalarial drug resistance, African malaria programs, therapeutic efficacy, lumefantrine exposure, artemisinin partial resistance, pharmacokinetics, treatment adherence, molecular surveillance, uncomplicated malaria, medicine quality, public health policy, extended regimens, combination therapy, clinical trials

News Source: Ophelia Keating. (November 18, 2026). Five-Day Malaria Regimen Requires Targeted Evaluation Across African Programs. Scienmag.

Tags: African malaria programsantimalarial drug resistanceartemether-lumefantrineartemisinin partial resistanceClinical Trialscombination therapyextended regimenslumefantrine exposureMalaria treatmentmedicine qualitymolecular surveillancePharmacokineticspublic health policyTherapeutic EfficacyTreatment adherenceuncomplicated malaria
Share12Tweet7Share2ShareShareShare1

Related Posts

Selective FLCN Inhibition Drives Lipid Secretion and Protects Mice From MAFLD

Selective FLCN Inhibition Drives Lipid Secretion and Protects Mice From MAFLD

November 18, 2026
Alex Zhavoronkov Named Highly Cited Researcher for Fourth Time in 2026

Alex Zhavoronkov Named Highly Cited Researcher for Fourth Time in 2026

November 18, 2026

Higher Insulin Sensitivity Estimator Linked to Lower Hypertension Odds in US Adults

November 18, 2026

Upadacitinib Prompts Hair Regrowth in Frontal Fibrosing Alopecia Case Report

November 18, 2026

POPULAR NEWS

  • Geospatial Proxies Reveal Stable Peri-Urban Health Units in Coastal Kenya

    Geospatial Proxies Reveal Stable Peri-Urban Health Units in Coastal Kenya

    29 shares
    Share 12 Tweet 7
  • Herbal Formula Alleviates Knee Osteoarthritis by Inhibiting Inflammatory Signaling in Rabbits

    29 shares
    Share 12 Tweet 7
  • First Single-Cell Microenvironment Atlas Maps Rare Lung Disease Lesions in Women

    29 shares
    Share 12 Tweet 7
  • Dissociative Corticosteroid Vamorolone Shows Differentiated Safety and Efficacy for DMD Treatment

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Uncertainty-Guided Graph Model Reaches 95.2 Percent Accuracy in Transformer Health Assessment

Selective FLCN Inhibition Drives Lipid Secretion and Protects Mice From MAFLD

Alex Zhavoronkov Named Highly Cited Researcher for Fourth Time in 2026

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.